These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9686611)

  • 21. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
    Bruenke J; Fischer B; Barbin K; Schreiter K; Wachter Y; Mahr K; Titgemeyer F; Niederweis M; Peipp M; Zunino SJ; Repp R; Valerius T; Fey GH
    Br J Haematol; 2004 Apr; 125(2):167-79. PubMed ID: 15059139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
    Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
    J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bispecific antibody treatment of murine B cell lymphoma.
    De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
    Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
    George AJ; Tutt AL; Stevenson FK
    J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo tumor immunotherapy by a bacterial superantigen.
    Ochi A; Migita K; Xu J; Siminovitch K
    J Immunol; 1993 Sep; 151(6):3180-6. PubMed ID: 8376773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
    Belani R; Weiner GJ
    J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
    Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
    Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
    Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
    Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific antibody therapy of two murine B-cell lymphomas.
    Demanet C; Brissinck J; Moser M; Leo O; Thielemans K
    Int J Cancer Suppl; 1992; 7():67-8. PubMed ID: 1428409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
    Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria.
    Kurucz I; Titus JA; Jost CR; Jacobus CM; Segal DM
    J Immunol; 1995 May; 154(9):4576-82. PubMed ID: 7536774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depletion of activated Vbeta8+ T cells disrupts bispecific antibody directed antitumor immunity.
    McConnell EJ; McLemore EC; Talac R; Joshi L; Nelson H
    J Surg Res; 2004 Nov; 122(1):103-12. PubMed ID: 15522322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.